Revance Therapeutics Inc (RVNC)

[vinmantoo]

Hey rock mountain, you hit the nail on the head.

Looking at Q4 22 and Q1 23 numbers, I expect max M 40 for RHA and M 22 for Daxxi for Q2 23. So if Q2 sales exceed M 65, I would be very happy.

I have linked the RVNC earnings report.

- Q2 total revenue of $58.1 million, a YoY increase of 104.9%.
- Q2 RHA® Collection revenue of $31.8 million, a YoY increase of 24.7%.
- Q2 DAXXIFY® revenue of $22.6 million, a QoQ increase of 47.1%.
- Bolstered financial position with $100 million net proceeds from ATM program and $50 million in notes available to be issued through Athyrium Capital on or before August 31, 2023.
- PDUFA date of August 19, 2023 for DAXXIFY® for the treatment of cervical dystonia.

https://investors.revance.com/news-releases/news-release-details/revance-reports-second-quarter-2023-financial-results-provides